Tonix Pharmaceuticals Holding Corp Business Update Transcript
Good morning, ladies and gentlemen and welcome to Tonix Pharmaceuticals Conference Call to discuss the result of the Phase 3 RELIEF study. At this time, all participants are in a listen-only mode. Later we will conduct a question-and-answer session. Instructions will follow at that time. As a reminder, this conference call is being recorded.
I would now like to turn the conference over to Peter Vozzo of Weswicke, Investor Relations for Tonix Pharmaceuticals. You may begin.
Thank you, [Jamie]. Good morning everyone and thank you for joining us today. We will review results of the Phase 3 RELIEF study of TNX-102 SL for fibromyalgia. Early this morning, the company issued a press relief announcing the result of the study.
On the call with me today are Tonix Pharmaceuticals' President and Chief Executive Officer, Dr. Seth Lederman and Chief Medical Officer, Dr. Greg Sullivan. Today's call is being made available via the Investor Relations section of the company's website at ir
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
